Wells GA - Search Results

1

How effects on health equity are assessed in systematic reviews of interventions.

Welch V, Dewidar O, Tanjong Ghogomu E, Abdisalam S, Al Ameer A, Barbeau VI, Brand K, Kebedom K, Benkhalti M, Kristjansson E, Madani MT, Antequera Martín AM, Mathew CM, McGowan J, McLeod W, Park HA, Petkovic J, Riddle A, Tugwell P, Petticrew M, Trawin J, Wells GA. Welch V, et al. Among authors: wells ga. Cochrane Database Syst Rev. 2022 Jan 18;1(1):MR000028. doi: 10.1002/14651858.MR000028.pub3. Cochrane Database Syst Rev. 2022. PMID: 35040487 Free PMC article. Review.

2

Endpoints in rheumatoid arthritis.

Tugwell P, Boers M, Baker P, Wells G, Snider J. Tugwell P, et al. J Rheumatol Suppl. 1994 Oct;42:2-8. J Rheumatol Suppl. 1994. PMID: 7823314

3

Users' guides to the medical literature. V. How to use an article about prognosis. Evidence-Based Medicine Working Group.

Laupacis A, Wells G, Richardson WS, Tugwell P. Laupacis A, et al. JAMA. 1994 Jul 20;272(3):234-7. doi: 10.1001/jama.272.3.234. JAMA. 1994. PMID: 8022043 No abstract available.

4

Cyclosporin A in rheumatoid arthritis: overview of efficacy.

Wells G, Tugwell P. Wells G, et al. Br J Rheumatol. 1993 Mar;32 Suppl 1:51-6. Br J Rheumatol. 1993. PMID: 8448639

5

Minimum important difference between patients with rheumatoid arthritis: the patient's perspective.

Wells GA, Tugwell P, Kraag GR, Baker PR, Groh J, Redelmeier DA. Wells GA, et al. J Rheumatol. 1993 Mar;20(3):557-60. J Rheumatol. 1993. PMID: 8478873

6

A cost effectiveness analysis of cyclosporine in rheumatoid arthritis.

Anis AH, Tugwell PX, Wells GA, Stewart DG. Anis AH, et al. Among authors: wells ga. J Rheumatol. 1996 Apr;23(4):609-16. J Rheumatol. 1996. PMID: 8730113

7

Impact of patient with patient interaction on perceived rheumatoid arthritis overall disease status.

Baker PR, Groh JD, Kraag GR, Tugwell P, Wells GA, Boisvert D. Baker PR, et al. Among authors: wells ga. Scand J Rheumatol. 1996;25(4):207-12. doi: 10.3109/03009749609069989. Scand J Rheumatol. 1996. PMID: 8792797

8

Implications of OMERACT outcomes in arthritis and osteoporosis for cochrane metaanalysis.

Cranney A, Tugwell P, Shea B, Wells G. Cranney A, et al. J Rheumatol. 1997 Jun;24(6):1206-7. J Rheumatol. 1997. PMID: 9195536 Clinical Trial.

9

Osteoporosis clinical trials endpoints: candidate variables and clinimetric properties.

Cranney A, Tugwell P, Cummings S, Sambrook P, Adachi J, Silman AJ, Gillespie WJ, Felson DT, Shea B, Wells G. Cranney A, et al. J Rheumatol. 1997 Jun;24(6):1222-9. J Rheumatol. 1997. PMID: 9195541 Clinical Trial.

10

Responsiveness of endpoints in osteoporosis clinical trials.

Wells G, Cranney A, Shea B, Tugwell P. Wells G, et al. J Rheumatol. 1997 Jun;24(6):1230-3. J Rheumatol. 1997. PMID: 9195542 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

818 results

Search Page